Followers | 4 |
Posts | 4327 |
Boards Moderated | 0 |
Alias Born | 12/11/2012 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, December 05, 2013 10:04:41 PM
VistaGen is a biotech small-cap applying its stem cell technology to revive once-promising drug candidates that were shelved due to heart and liver safety concerns. Pharmaceutical companies spend millions of dollars and decades of time researching new drug candidates to advance them into clinical development. If the drug candidate fails to achieve a favorable safety profile in late-stage preclinical development, further development often grinds to a halt, and with it, the potential therapeutic and commercial benefits.
Approximately one-third of all potential new drug candidates fail in preclinical or clinical trials due to safety concerns, leaving a wake of lame-duck therapeutic possibilities that could save lives and advance science in leaps and bounds.
This is where VistaGen takes the baton. The company believes that valuable accuracy and application are lost in testing animal subjects, which only approximate human biology and can lead to unexpected safety issues. Conversely, VistaGen aims to provide predictive toxicology and metabolism screening systems that more closely approximate human biology in early development phases.
Leveraging its Human Clinical Trials in a Test Tube™ platform, VistaGen is positioned to have a “head start” in the identification and development of new, proprietary Drug Rescue Variants in a more rapid and less expensive manner than drug candidates discovered and developed using conventional and in vitro cell culture testing.
The technology allows for the controlled differentiation of human pluripotent stem cells into mature, functional human cells, which may allow researchers to identify human toxicity or metabolism issues early in the drug development process, saving money and freeing up resources to focus on drug candidates with the highest probability of success.
VistaGen believes that this capability has the potential to significantly reduce drug development costs, while producing effective and safer drugs.
For more information, visit http://www.VistaGen.com
EXPERIENCE IS THE BEST TEACHER, BUT IT IS THE MOST EXPENSIVE
MY OPINIONS ARE MY OWN AND DUE DILIGENCE I POST SHOULD BE CONFIRMED AS UNBIASED,EVERYTHING POSTED IS OFCOURSE IN MY HUMBLE OPINION
Element79 Gold Corp Appoints Warren Levy to Board of Directors • ELMGF • Aug 28, 2024 9:51 AM
Integrated Ventures Announces Strategic Entry Into Health & Wellness Industry with Focus on GLP-1 Products • INTV • Aug 28, 2024 8:30 AM
ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • ELMGF • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM